These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6971630)

  • 41. SCH 23390 and SK&F 83566 are antagonists at vascular dopamine and serotonin receptors.
    Ohlstein EH; Berkowitz BA
    Eur J Pharmacol; 1985 Jan; 108(2):205-8. PubMed ID: 3884345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning.
    Ushijima I; Mizuki Y; Yamada M
    Psychopharmacology (Berl); 1988; 95(1):34-7. PubMed ID: 3133698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine.
    Miller R; Beninger RJ
    Prog Neurobiol; 1991; 36(3):229-56. PubMed ID: 1673254
    [No Abstract]   [Full Text] [Related]  

  • 44. Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus.
    Starke K; Späth L; Lang JD; Adelung C
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Aug; 323(4):298-306. PubMed ID: 6605484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor.
    O'Boyle KM; Gaitanopoulos DE; Brenner M; Waddington JL
    Neuropharmacology; 1989 Apr; 28(4):401-5. PubMed ID: 2568596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antagonism of the renal vasodilator activity of dopamine by metoclopramide.
    Hahn RA; Wardell JR
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Nov; 314(2):177-82. PubMed ID: 7453834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroinhibitory effects of SK&F 85174, a novel dopamine receptor agonist.
    Blumberg AL; Wilson JW; Hieble JP
    J Cardiovasc Pharmacol; 1985; 7(4):723-32. PubMed ID: 2410714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of bromocriptine on neurogenic vasoconstriction in the isolated autoperfused hindquarters of the rat.
    Roquebert J; Alaoui K; Morán A
    Fundam Clin Pharmacol; 1990; 4(5):539-45. PubMed ID: 2289745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ergometrine and apomorphine as selective antagonists of dopamine in the canine renal vasculature.
    Bell C; Conway EL; Lang WJ
    Br J Pharmacol; 1974 Dec; 52(4):591-5. PubMed ID: 4455334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vasodilator response to dopamine in the ferret pulmonary circulation.
    Gorman P
    Br J Pharmacol; 1988 May; 94(1):212-8. PubMed ID: 2900036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK & F 38393 and its R- and S-enantiomers in the intact adult rat.
    Molloy AG; Waddington JL
    Psychopharmacology (Berl); 1987; 92(2):164-8. PubMed ID: 3110837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
    Kaiser C; Dandridge PA; Garvey E; Hahn RA; Sarau HM; Setler PE; Bass LS; Clardy J
    J Med Chem; 1982 Jun; 25(6):697-703. PubMed ID: 6980283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice.
    Jackson DM; Ross SB; Hashizume M
    Psychopharmacology (Berl); 1988; 94(3):321-7. PubMed ID: 2895938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.
    Gerhardt S; Gerber R; Liebman JM
    Life Sci; 1985 Dec; 37(25):2355-63. PubMed ID: 3908866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of Ca2+ channel blockers on apomorphine, bromocriptine and morphine-induced locomotor activity in mice.
    Doğrul A; Yeşilyurt O
    Eur J Pharmacol; 1999 Jan; 364(2-3):175-82. PubMed ID: 9932721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
    Weinstock J; Wilson JW; Ladd DL; Brush CK; Pfeiffer FR; Kuo GY; Holden KG; Yim NC; Hahn RA; Wardell JR; Tobia AJ; Setler PE; Sarau HM; Ridley PT
    J Med Chem; 1980 Sep; 23(9):973-5. PubMed ID: 7411552
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative studies of cardiovascular effects of a new dopamine agonist (SK&F 38393A) and dopamine.
    Tsai CS; Ochillo RF
    Gen Pharmacol; 1985; 16(2):85-9. PubMed ID: 3873379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different dopamine receptor subtypes mediate the neurogenic vasodilation produced by fenoldopam and SK & F 85174 in the dog hindlimb.
    Lokhandwala MF; Watkins HO; Dlewati A
    Eur J Pharmacol; 1987 Nov; 143(3):383-90. PubMed ID: 2891555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vascular dopamine receptors: Demonstration and characterization by in vitro studies.
    Brodde OE
    Life Sci; 1982 Jul; 31(4):289-306. PubMed ID: 6292644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine-like renal and mesenteric vasodilation caused by apomorphine 6-propylnorapomorphine and 2-amino-6, 7-dihydroxy-1,2,3,4-tetrahydronaphthalene.
    Crumly HJ; Pinder RM; Hinshaw WB; Goldberg LI
    Nature; 1976 Feb; 259(5544):584-7. PubMed ID: 1250405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.